Investigations on the influence of terminal groups at the C2-propyl side chain of 1,1-bis(4-hydroxyphenyl)-2-phenylpent-1-ene and 1,1,2-tris(4-hydroxyphenyl)pent-1-ene on the estrogen receptor binding and the estrogenic/anti-estrogenic properties

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 1, 2003, Pages 57-70

  Gust, Ronald ^a   Lubczyk, Veronika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Anti estrogenic activity; Estrogen receptor binding; Luciferase assay; Triarylalkenes

Indexed keywords

1,1 BIS(4 HYDROXYPHENYL) 2 PHENYL 5 ACETAMIDOPENT 1 ENE; 1,1 BIS(4 HYDROXYPHENYL) 2 PHENYL 5 AMINOPENT 1 ENE; 1,1 BIS(4 HYDROXYPHENYL) 2 PHENYL 5 CYANOPENT 1 ENE; 1,1 BIS(4 HYDROXYPHENYL) 2 PHENYL 5 PROPIONAMIDOPENT 1 ENE; 1,1,2 TRIS(4 HYDROXYPHENYL) 2 PHENYL 5 ACETAMIDOPENT 1 ENE; 1,1,2 TRIS(4 HYDROXYPHENYL) 2 PHENYL 5 PROPIONAMIDOPENT 1 ENE; 1,1,2 TRIS(4 HYDROXYPHENYL) 5 AMINOPENT 1 ENE; 1,1,2 TRIS(4 HYDROXYPHENYL) 5 CYANOPENT 1 ENE; ALKENE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENCY; ESTROGEN ACTIVITY; GENETIC TRANSFECTION; HORMONE RECEPTOR INTERACTION; PLASMID; SYNTHESIS;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0041887177     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00253-X     Document Type: Article

References (31)

1. Tsai M.-J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
2. Beato M., Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocrinol. Rev. 17:1996;587-609.
3. Hager G.L., Lim C.S., Elbi C., Baumann C.T. Trafficking of nuclear receptors in living cells. J. Steroid Biochem. Mol. Biol. 74:2000;249-254.
4. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.W., Bonn T., Engström O., Öhman L., Greene G.L., Gustafsson J.-Å., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
5. Feng W., Ribeiro R.C.J., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., West B.L. Hormone dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749.
6. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res. 50:1990;4177-4189.
7. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
8. Lubczyk V., Bachmann H., Gust R. Investigations on the estrogen receptor binding. The estrogenic, antiestrogenic and cytotoxic properties of C2-alkyl substituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes. J. Med. Chem. 45:2002;5358-5364.
9. Lubczyk V., Bachmann H., Gust R. Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain. Synthesis and biological activity. J. Med. Chem. 46:2003;1484-1491.
10. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., Katzenellenbogen J.A., Agard D.A., Greene G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen antagonism. Nat. Struct. Biol. 9:2002;359-364.
11. Meyers M.J., Sun J., Carlson K.E., Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl-5,6,11,12-tetrahydrochrysenes. J. Med. Chem. 42:1999;2456-2468.
12. Sun J., J Meyers M., E Fink B., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology. 140:1999;800-804.
13. Hay R.J. The seed stock concept and quality control for cell lines. Anal. Biochem. 171:1988;225-237.
14. Hartmann R., Kranzfelder G., von Angerer E., Schönenberger H. Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2-diphenylethanes. J. Med. Chem. 23:1980;841-847.
15. Hafner F., Holler E., von Angerer E. Effect of growth factors on estrogen receptor mediated gene expression. J. Steroid Biochem. Mol. Biol. 58:1996;385-393.
16. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
17. Dodds E., Golberg L., Lawson W., Robinson R. Synthetic estrogenic compounds related to stilbene and diphenylethaneIII. Proc. R. Soc. Lond. Ser. B. 127:1939;140-167.
18. Jones C.D., Jevnikar M.G., Pike A.J., Peters M.K., Black L.J., Thompson A.R., Falcone J.F., Clemens J.A. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27:1984;1057-1066.
19. Liu H., Park W.C., Bentrem D.J., McKian K.P., De Los R.A., Loweth J.A., MacGregor Schafer J., Zapf J.W., Jordan V.C. Structure-function relationships of the raloxifene-estrogen receptor-α complex for regulating transforming growth factor-α expression in breast cancer cells. J. Biol. Chem. 277:2002;9189-9198.
20. Schuderer M.L., Schneider M.R. Cytotoxic esters of 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene with selective antitumor activity against estrogen receptor-containing mammary tumors. J. Cancer Res. Clin. Oncol. 113:1987;230-234.
21. Schneider M.R. 2-Alkyl-substituted 1,1-bis(4-acetoxyphenyl)-2-phenylethenes. Estrogen receptor affinity, estrogenic and antiestrogenic properties, and mammary tumor inhibiting activity. J. Med. Chem. 29:1986;1494-1498.
22. Schuderer M.L., Schneider M.R. Influence of derivatisation of the hydroxy groups in 1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene on estradiol receptor affinity and mammary tumor inhibiting properties. Arch. Pharm. 320:1987;635-641.
23. Schneider M.R., von Angerer E., Prekajac J., Brade W.P. Studies on the mammary tumor-inhibiting effects of diethylstilbestrol and its mono- and diphosphate. J. Cancer Res. Clin. Oncol. 111:1986;110-114.
24. 7 cell proliferation. J. Med. Chem. 35:1992;573-583.
25. Bignon E., Pons M., Crastes de Paulet A., Doré J.-C., Gilbert J., Abecassis J., Miquel J.-F., Ojasoo T., Raynaud J.-P. Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on human breast cancer cell growth. J. Med. Chem. 32:1989;2092-2103.
26. Miquel J.-F., Sekera A.S., Chaudron T. Synthèse de polyphényléthylènes et interferences avec le récepteur œstrogène d'utérus de souris. C. R. Acad. Sci. Paris. Ser. C. 286:1978;151-154.
27. Pike A.C., Brzozowski A.M., Walton J., Hubbard R.E., Thorsell A.G., Li Y.L., Gustafsson J.A., Carlquist M. Structural insights into the mode of action of a pure antiestrogen. Structure. 9:2001;145-153.
28. Fawell S.E., Lees J.A., White R., Parker M.G. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell. 60:1990;953-962.
29. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4037-4041.
30. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182 780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106:1993;1377-1388.
31. Gust R., Keilitz R., Schmidt K., von Rauch M. (4R,5S)/(4S,5R)-4,5-bis(4-Hydroxyphenyl)-2-imidazolines: ligands for the estrogen receptor with a novel binding mode. J. Med. Chem. 45:2002;3356-3365.